Investigational drug · Phase 3
DW51212
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Bronchitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "DW51212"
First trial start
2024
Mar 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DW51212", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Bronchitis
Largest trials
Live from ClinicalTrials.gov: studies naming "DW51212" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212Pivotal-lookingCompleted
Daewon Pharmaceutical Co., Ltd.Industry
NCT07093697 · 273 participants · Start Mar 28, 2024 · Primary completion May 27, 2025
Drug: DW5121; DW51211 and 1 more · For: Acute Bronchitis
Sites: Bucheon-si, South Korea; Chuncheon, South Korea; Daegu, South Korea · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Acute Bronchitis
- RaphaminMMH-407Phase 35 trials
Materia Medica Holding · Rhinosinusitis, Rhinosinusitis Acute, Cystitis Chronic
- AG2001Phase 31 trial
Ahn-Gook Pharmaceuticals Co.,Ltd · Acute Bronchitis
- AG20011Phase 31 trial
Ahn-Gook Pharmaceuticals Co.,Ltd · Acute Bronchitis
- AG20012Phase 31 trial
Ahn-Gook Pharmaceuticals Co.,Ltd · Acute Bronchitis
- DW5121Phase 31 trial
Daewon Pharmaceutical Co., Ltd. · Acute Bronchitis
- DW51211Phase 31 trial
Daewon Pharmaceutical Co., Ltd. · Acute Bronchitis
- YHP2401Phase 31 trial
Yuhan Corporation · Acute Bronchitis
- YHR2402Phase 31 trial
Yuhan Corporation · Acute Bronchitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.